Biologic predictors of serologic responses to HPV in oropharyngeal cancer: The HOTSPOT study

Karen Anderson, Jennifer E. Gerber, Gypsyamber D'Souza, Sara I. Pai, Julia N. Cheng, Rizwan Alam, Sailaja Kesiraju, Diego Chowell, Neil D. Gross, Robert Haddad, Maura L. Gillison, Marshall Posner

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Objectives: We hypothesized that viral and host factors impact the serologic responses to HPV early antigens in HPV-positive oropharyngeal cancer (HPVOPC). Materials and methods: We conducted a multicenter study to measure HPV16-specific IgG among patients with HPVOPC, their long-term sexual partners, and healthy volunteers. Risk factor surveys and rinse and gargle specimens were collected. Peripheral blood samples at diagnosis were evaluated for IgG Abs to HPV16 antigens using a programmable ELISA assay. Predictors for HPV16 serologic responses were evaluated using univariate and multivariable linear regression. Results: 116 patients with HPVOPC, 43 partners, and 81 healthy volunteers were enrolled and had baseline sera for analysis. Cases were primarily male (90%), with a median age of 56 years. Abs to E1, E2, E6 or E7 antigens were detected more often in HPVOPC compared with volunteers or partner sera (p <0.0001). HPV16 Abs to at least one early protein (E1, E2, E4, E5, E6, or E7) were detected in the sera of 90.6% of cases, 0% of partners and 7.4% of healthy volunteers. Gender, race, sexual behavior, and viral integration were not associated with antibody response. Younger age and higher oral HPV16 copy number were associated with higher HPV16 E6 and NE2 antibody levels. Conclusions: HPV16 seroreactivity is commonly detected among patients with HPVOPC at diagnosis, but not among partners or healthy volunteers. Seroreactivity among cases are correlated with viral load and stage and not with other demographic or behavioral factors. Positive HPV16 serology was strongly associated with HPV 16 oropharyngeal cancer.

Original languageEnglish (US)
Pages (from-to)751-758
Number of pages8
JournalOral Oncology
Volume51
Issue number8
DOIs
StatePublished - 2015

Fingerprint

Oropharyngeal Neoplasms
Healthy Volunteers
Antigens
Immunoglobulin G
Serum
Virus Integration
Human papillomavirus 16
Sexual Partners
Serology
Viral Load
Sexual Behavior
Multicenter Studies
Antibody Formation
Volunteers
Linear Models
Enzyme-Linked Immunosorbent Assay
Demography
Antibodies

Keywords

  • Antibodies
  • Biomarker
  • HPV
  • Oropharyngeal cancer
  • Serology

ASJC Scopus subject areas

  • Oncology
  • Oral Surgery
  • Cancer Research

Cite this

Biologic predictors of serologic responses to HPV in oropharyngeal cancer : The HOTSPOT study. / Anderson, Karen; Gerber, Jennifer E.; D'Souza, Gypsyamber; Pai, Sara I.; Cheng, Julia N.; Alam, Rizwan; Kesiraju, Sailaja; Chowell, Diego; Gross, Neil D.; Haddad, Robert; Gillison, Maura L.; Posner, Marshall.

In: Oral Oncology, Vol. 51, No. 8, 2015, p. 751-758.

Research output: Contribution to journalArticle

Anderson, K, Gerber, JE, D'Souza, G, Pai, SI, Cheng, JN, Alam, R, Kesiraju, S, Chowell, D, Gross, ND, Haddad, R, Gillison, ML & Posner, M 2015, 'Biologic predictors of serologic responses to HPV in oropharyngeal cancer: The HOTSPOT study', Oral Oncology, vol. 51, no. 8, pp. 751-758. https://doi.org/10.1016/j.oraloncology.2015.05.007
Anderson, Karen ; Gerber, Jennifer E. ; D'Souza, Gypsyamber ; Pai, Sara I. ; Cheng, Julia N. ; Alam, Rizwan ; Kesiraju, Sailaja ; Chowell, Diego ; Gross, Neil D. ; Haddad, Robert ; Gillison, Maura L. ; Posner, Marshall. / Biologic predictors of serologic responses to HPV in oropharyngeal cancer : The HOTSPOT study. In: Oral Oncology. 2015 ; Vol. 51, No. 8. pp. 751-758.
@article{9c4e56c313214b9bb1601a334689d3ce,
title = "Biologic predictors of serologic responses to HPV in oropharyngeal cancer: The HOTSPOT study",
abstract = "Objectives: We hypothesized that viral and host factors impact the serologic responses to HPV early antigens in HPV-positive oropharyngeal cancer (HPVOPC). Materials and methods: We conducted a multicenter study to measure HPV16-specific IgG among patients with HPVOPC, their long-term sexual partners, and healthy volunteers. Risk factor surveys and rinse and gargle specimens were collected. Peripheral blood samples at diagnosis were evaluated for IgG Abs to HPV16 antigens using a programmable ELISA assay. Predictors for HPV16 serologic responses were evaluated using univariate and multivariable linear regression. Results: 116 patients with HPVOPC, 43 partners, and 81 healthy volunteers were enrolled and had baseline sera for analysis. Cases were primarily male (90{\%}), with a median age of 56 years. Abs to E1, E2, E6 or E7 antigens were detected more often in HPVOPC compared with volunteers or partner sera (p <0.0001). HPV16 Abs to at least one early protein (E1, E2, E4, E5, E6, or E7) were detected in the sera of 90.6{\%} of cases, 0{\%} of partners and 7.4{\%} of healthy volunteers. Gender, race, sexual behavior, and viral integration were not associated with antibody response. Younger age and higher oral HPV16 copy number were associated with higher HPV16 E6 and NE2 antibody levels. Conclusions: HPV16 seroreactivity is commonly detected among patients with HPVOPC at diagnosis, but not among partners or healthy volunteers. Seroreactivity among cases are correlated with viral load and stage and not with other demographic or behavioral factors. Positive HPV16 serology was strongly associated with HPV 16 oropharyngeal cancer.",
keywords = "Antibodies, Biomarker, HPV, Oropharyngeal cancer, Serology",
author = "Karen Anderson and Gerber, {Jennifer E.} and Gypsyamber D'Souza and Pai, {Sara I.} and Cheng, {Julia N.} and Rizwan Alam and Sailaja Kesiraju and Diego Chowell and Gross, {Neil D.} and Robert Haddad and Gillison, {Maura L.} and Marshall Posner",
year = "2015",
doi = "10.1016/j.oraloncology.2015.05.007",
language = "English (US)",
volume = "51",
pages = "751--758",
journal = "Oral Oncology",
issn = "1368-8375",
publisher = "Elsevier Limited",
number = "8",

}

TY - JOUR

T1 - Biologic predictors of serologic responses to HPV in oropharyngeal cancer

T2 - The HOTSPOT study

AU - Anderson, Karen

AU - Gerber, Jennifer E.

AU - D'Souza, Gypsyamber

AU - Pai, Sara I.

AU - Cheng, Julia N.

AU - Alam, Rizwan

AU - Kesiraju, Sailaja

AU - Chowell, Diego

AU - Gross, Neil D.

AU - Haddad, Robert

AU - Gillison, Maura L.

AU - Posner, Marshall

PY - 2015

Y1 - 2015

N2 - Objectives: We hypothesized that viral and host factors impact the serologic responses to HPV early antigens in HPV-positive oropharyngeal cancer (HPVOPC). Materials and methods: We conducted a multicenter study to measure HPV16-specific IgG among patients with HPVOPC, their long-term sexual partners, and healthy volunteers. Risk factor surveys and rinse and gargle specimens were collected. Peripheral blood samples at diagnosis were evaluated for IgG Abs to HPV16 antigens using a programmable ELISA assay. Predictors for HPV16 serologic responses were evaluated using univariate and multivariable linear regression. Results: 116 patients with HPVOPC, 43 partners, and 81 healthy volunteers were enrolled and had baseline sera for analysis. Cases were primarily male (90%), with a median age of 56 years. Abs to E1, E2, E6 or E7 antigens were detected more often in HPVOPC compared with volunteers or partner sera (p <0.0001). HPV16 Abs to at least one early protein (E1, E2, E4, E5, E6, or E7) were detected in the sera of 90.6% of cases, 0% of partners and 7.4% of healthy volunteers. Gender, race, sexual behavior, and viral integration were not associated with antibody response. Younger age and higher oral HPV16 copy number were associated with higher HPV16 E6 and NE2 antibody levels. Conclusions: HPV16 seroreactivity is commonly detected among patients with HPVOPC at diagnosis, but not among partners or healthy volunteers. Seroreactivity among cases are correlated with viral load and stage and not with other demographic or behavioral factors. Positive HPV16 serology was strongly associated with HPV 16 oropharyngeal cancer.

AB - Objectives: We hypothesized that viral and host factors impact the serologic responses to HPV early antigens in HPV-positive oropharyngeal cancer (HPVOPC). Materials and methods: We conducted a multicenter study to measure HPV16-specific IgG among patients with HPVOPC, their long-term sexual partners, and healthy volunteers. Risk factor surveys and rinse and gargle specimens were collected. Peripheral blood samples at diagnosis were evaluated for IgG Abs to HPV16 antigens using a programmable ELISA assay. Predictors for HPV16 serologic responses were evaluated using univariate and multivariable linear regression. Results: 116 patients with HPVOPC, 43 partners, and 81 healthy volunteers were enrolled and had baseline sera for analysis. Cases were primarily male (90%), with a median age of 56 years. Abs to E1, E2, E6 or E7 antigens were detected more often in HPVOPC compared with volunteers or partner sera (p <0.0001). HPV16 Abs to at least one early protein (E1, E2, E4, E5, E6, or E7) were detected in the sera of 90.6% of cases, 0% of partners and 7.4% of healthy volunteers. Gender, race, sexual behavior, and viral integration were not associated with antibody response. Younger age and higher oral HPV16 copy number were associated with higher HPV16 E6 and NE2 antibody levels. Conclusions: HPV16 seroreactivity is commonly detected among patients with HPVOPC at diagnosis, but not among partners or healthy volunteers. Seroreactivity among cases are correlated with viral load and stage and not with other demographic or behavioral factors. Positive HPV16 serology was strongly associated with HPV 16 oropharyngeal cancer.

KW - Antibodies

KW - Biomarker

KW - HPV

KW - Oropharyngeal cancer

KW - Serology

UR - http://www.scopus.com/inward/record.url?scp=84942827166&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942827166&partnerID=8YFLogxK

U2 - 10.1016/j.oraloncology.2015.05.007

DO - 10.1016/j.oraloncology.2015.05.007

M3 - Article

C2 - 26094591

AN - SCOPUS:84942827166

VL - 51

SP - 751

EP - 758

JO - Oral Oncology

JF - Oral Oncology

SN - 1368-8375

IS - 8

ER -